Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532402

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532402

Immuno-oncology Drugs Market, By Treatment Type, By Disease Type, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Global immuno-oncology drugs market is estimated to be valued at USD 27.25 Bn in 2024 and is expected to reach USD 89.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.4% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 27.25 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 18.40% 2031 Value Projection: US$ 89.10 Bn
Figure. Immuno-oncology Drugs Market Share (%), By Region 2024
Immuno-oncology Drugs Market - IMG1

Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

  • This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

  • By Treatment Type
    • Immune Checkpoint Inhibitors
    • PD-1
    • PD-LI
    • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Oncolytic Virus
    • Others
  • By Disease Type
    • Melanoma
    • Lung Cancer
    • Blood Cancer
    • Renal Cell Carcinoma
    • Prostate Cancer
    • Bladder Cancer
    • Others (Breast Cancer, Thyroid Cancer, etc.)
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Coloplast Corp
    • Bristol Myers Squibb Company
    • Novartis AG
    • F. Hoffmann-LA Roche Ltd.
    • Merck & Co., Inc.
    • GSK Plc.
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Genentech Inc.
    • Sanofi
    • AstraZeneca
    • Bayer AG
    • Bluebird Bio, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Amgen Inc.
Product Code: CMI1271

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Immune Checkpoint Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • PD-1
  • PD-LI
  • CTLA-4
  • Immune System Modulators
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Cancer Vaccines
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Oncolytic Virus
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Melanoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Lung Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Blood Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Renal Cell Carcinoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Prostate Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Bladder Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Immuno-oncology Drugs Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Coloplast Corp
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bristol Myers Squibb Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F. Hoffmann-LA Roche Ltd.
    • Merck & Co., Inc.
    • GSK Plc.
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Genentech Inc.
    • Sanofi
    • AstraZeneca
    • Bayer AG
    • Bluebird Bio, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Amgen Inc.

10. Analyst Recommendation

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!